New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

The Lancet Oncology

Volumn 20, Issue 1, 2019, Pages e54-e64

  Martins, Filipe ^a,b   Sykiotis, Gerasimos P ^a   Maillard, Michel ^a,c   Fraga, Montserrat ^a   Ribi, Camillo ^a   Kuntzer, Thierry ^a   Michielin, Olivier ^a   Peters, Solange ^a   Coukos, Georges ^a,d   Spertini, Francois ^a   Thompson, John A ^e,f   Obeid, Michel ^a,g  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EPFL   (Switzerland)

^c Crohn and Colitis Center   (Switzerland)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^e USA   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CD20 ANTIBODY; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 6 ANTIBODY; JANUS KINASE INHIBITOR; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; NATALIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

DRUG INDUCED DISEASE; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASM; NONHUMAN; NOTE; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT INDICATION; ADVERSE DRUG REACTION; ADVERSE EVENT; ALGORITHM; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; NEOPLASMS; PRECISION MEDICINE;

EID: 85059348176     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30828-3     Document Type: Note

References (84)

1. Kong, BY, Micklethwaite, KP, Swaminathan, S, Kefford, RF, Carlino, MS, Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res 26 (2016), 202–204.
2. Delyon, J, Mateus, C, Lambert, T, Hemophilia A induced by ipilimumab. N Engl J Med 365 (2011), 1747–1748.
3. Wolchok, JD, Chiarion-Sileni, V, Gonzalez, R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377 (2017), 1345–1356.
4. Haanen, J, Carbonnel, F, Robert, C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:suppl 4 (2017), iv119–iv142.
5. Puzanov, I, Diab, A, Abdallah, K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 5, 2017, 95.
6. National Comprehensive Cancer Network. Management of immunotherapy-related toxicities. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. (Accessed 14 February 2018)
7. Horvat, TZ, Adel, NG, Dang, TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33 (2015), 3193–3198.
8. Stroud, CR, Hegde, A, Cherry, C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract, 2017 published online Jan 1. DOI:1078155217745144.
9. Mahmood, SS, Fradley, MG, Cohen, JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 (2018), 1755–1764.
10. Wang, DY, Salem, JE, Cohen, JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol, 2018 published online Sep 13. DOI:10.1001/jamaoncol.2018.3923.
11. Geukes Foppen, MH, Rozeman, EA, van Wilpe, S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open, 3, 2018, e000278.
12. Zen, Y, Yeh, MM, Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 31 (2018), 965–973.
13. McGuire, HM, Shklovskaya, E, Edwards, J, et al. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother 67 (2018), 563–573.
14. Spankuch, I, Gassenmaier, M, Tampouri, I, et al. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. Eur J Cancer 81 (2017), 203–205.
15. Chmiel, KD, Suan, D, Liddle, C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29 (2011), e237–e240.
16. Chen, JH, Lee, KY, Hu, CJ, Chung, CC, Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore), 96, 2017, e9262.
17. Huh, SY, Shin, SH, Kim, MK, Lee, SY, Son, KH, Shin, HY, Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer. J Clin Neurol 14 (2018), 115–117.
18. Touat, M, Talmasov, D, Ricard, D, Psimaras, D, Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30 (2017), 659–668.
19. Zeissig, S, Petersen, BS, Tomczak, M, et al. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. Gut 64 (2015), 1889–1897.
20. Fisher, DT, Appenheimer, MM, Evans, SS, The two faces of IL-6 in the tumor microenvironment. Semin Immunol 26 (2014), 38–47.
21. Landskron, G, De la Fuente, M, Thuwajit, P, Thuwajit, C, Hermoso, MA, Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res, 2014, 2014, 1491.
22. Cheng, R, Cooper, A, Kench, J, et al. Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 30 (2015), 657–666.
23. Ortega Sanchez, G, Jahn, K, Savic, S, Zippelius, A, Laubli, H, Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. J Immunother Cancer, 6, 2018, 85.
24. Oke, AR, Wheater, M, Karydis, I, Wallis, D, Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis. Rheumatol Adv Pract, 2, 2018 rky001-rky.
25. Weiler-Normann, C, Schramm, C, Quaas, A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 58 (2013), 529–534.
26. Toussirot, E, Aubin, F, Paradoxical reactions under TNF-alpha blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open, 2, 2016, e000239.
27. Wallis, RS, Broder, MS, Wong, JY, Hanson, ME, Beenhouwer, DO, Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 (2004), 1261–1265.
28. Lucas, SM, Rothwell, NJ, Gibson, RM, The role of inflammation in CNS injury and disease. Br J Pharmacol 147:suppl 1 (2006), s232–s240.
29. Norwood, TG, Westbrook, BC, Johnson, DB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer, 5, 2017, 91.
30. Jiang, H, Gebhardt, C, Umansky, L, et al. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer 136 (2015), 2352–2360.
31. Murray, KN, Parry-Jones, AR, Allan, SM, Interleukin-1 and acute brain injury. Front Cell Neurosci, 9, 2015, 18.
32. Sutton, C, Brereton, C, Keogh, B, Mills, KH, Lavelle, EC, A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 203 (2006), 1685–1691.
33. Durrant, DM, Robinette, ML, Klein, RS, IL-1R1 is required for dendritic cell-mediated T cell reactivation within the CNS during West Nile virus encephalitis. J Exp Med 210 (2013), 503–516.
34. Harrison, SR, McGonagle, D, Nizam, S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight, 6, 2016, e86336.
35. Cappelli, LC, Shah, AA, Bingham, CO, et al. Immune-related adverse effects of cancer immunotherapy- implications for rheumatology. Rheum Dis Clin North Am 43 (2017), 65–78.
36. Laird, BJ, Fallon, M, Hjermstad, MJ, et al. Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response. J Clin Oncol 34 (2016), 2769–2775.
37. Brulhart, L, Nissen, MJ, Chevallier, P, Gabay, C, Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 77 (2010), 625–626.
38. Shimamoto, K, Ito, T, Ozaki, Y, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol 40 (2013), 1074–1081.
39. Lippitz, BE, Harris, RA, Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology, 5, 2016, e1093722.
40. Dayer, JM, Choy, E, Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 49 (2010), 15–24.
41. Hirano, T, Ohguro, N, Hohki, S, et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 22 (2012), 298–302.
42. Perdan-Pirkmajer, K, Praprotnik, S, Tomsic, M, A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol 29 (2010), 1465–1467.
43. Muselier, A, Bielefeld, P, Bidot, S, Vinit, J, Besancenot, JF, Bron, A, Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 19 (2011), 382–383.
44. Perez-Moreiras, JV, Alvarez-Lopez, A, Gomez, EC, Treatment of active corticosteroid-resistant Graves' orbitopathy. Ophthalmic Plast Reconstr Surg 30 (2014), 162–167.
45. Jonsson, DI, Pirskanen, R, Piehl, F, Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord 27 (2017), 565–568.
46. Xie, F, Yun, H, Bernatsky, S, Curtis, JR, Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol 68 (2016), 2612–2617.
47. Strangfeld, A, Richter, A, Siegmund, B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 76 (2017), 504–510.
48. Callahan, MK, Yang, A, Tandon, S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol, 29(suppl 15), 2011, 2505.
49. Fabre, J, Giustiniani, J, Garbar, C, et al. Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type. Int J Mol Sci, 17, 2016, 1433.
50. Esfahani, K, Miller, WH Jr, Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 376 (2017), 1989–1991.
51. Feagan, BG, Sandborn, WJ, Gasink, C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 375 (2016), 1946–1960.
52. Teng, MW, Vesely, MD, Duret, H, et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 72 (2015), 3987–3996.
53. Deepak, P, Loftus, EV Jr, Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. Drug Des Devel Ther 10 (2016), 3685–3698.
54. Hottinger, AF, de Micheli, R, Guido, V, Karampera, A, Hagmann, P, Du Pasquier, R, Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis. Neurol Neuroimmunol Neuroinflamm, 5, 2018, e439.
55. Singh, H, Grewal, N, Arora, E, Kumar, H, Kakkar, AK, Vedolizumab: a novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med 7 (2016), 4–9.
56. Bergqvist, V, Hertervig, E, Gedeon, P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 66 (2017), 581–592.
57. Sandborn, WJ, Su, C, Panes, J, Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 377 (2017), 496–497.
58. Iwama, S, De Remigis, A, Callahan, MK, Slovin, SF, Wolchok, JD, Caturegli, P, Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med, 6, 2014, 230ra45.
59. Naidoo, J, Schindler, K, Querfeld, C, et al. autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 4 (2016), 383–389.
60. Osorio, JC, Ni, A, Chaft, JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28 (2017), 583–589.
61. Das, R, Bar, N, Ferreira, M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 128 (2018), 715–720.
62. Liudahl, SM, Coussens, LM, B cells as biomarkers: predicting immune checkpoint therapy adverse events. J Clin Invest 28 (2018), 577–579.
63. Sene, D, Jallouli, M, Lefaucheur, JP, et al. Peripheral neuropathies associated with primary Sjogren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine (Baltimore) 90 (2011), 133–138.
64. Mekinian, A, Ravaud, P, Hatron, PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 71 (2012), 84–87.
65. Chung, L, Funke, AA, Chakravarty, EF, Callen, JP, Fiorentino, DF, Successful use of rituximab for cutaneous vasculitis. Arch Dermatol 142 (2006), 1407–1410.
66. Novikov, P, Moiseev, S, Smitienko, I, Zagvozdkina, E, Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: a report of 6 cases. Joint Bone Spine 83 (2016), 81–84.
67. Williams, TJ, Benavides, DR, Patrice, KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73 (2016), 928–933.
68. Papadopoulos, KP, Romero, RS, Gonzalez, G, Dix, JE, Lowy, I, Fury, M, Anti-hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 23 (2018), 118–120.
69. Ito, M, Fujiwara, S, Fujimoto, D, et al. Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. Ann Oncol 28 (2017), 2318–2319.
70. Burak, KW, Swain, MG, Santodomingo-Garzon, T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 27 (2013), 273–280.
71. Somasundaram, R, Zhang, G, Fukunaga-Kalabis, M, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun, 8, 2017, 607.
72. Fang, D, Nguyen, TK, Leishear, K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65 (2005), 9328–9337.
73. Winkler, JK, Schiller, M, Bender, C, Enk, AH, Hassel, JC, Rituximab as a therapeutic option for patients with advanced melanoma. Cancer Immunol Immunother 67 (2018), 917–924.
74. Stohl, W, Schwarting, A, Okada, M, Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69 (2017), 1016–1027.
75. Tai, YT, Mayes, PA, Acharya, C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123 (2014), 3128–3138.
76. Tanaka, R, Maruyama, H, Tomidokoro, Y, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barre syndrome: a case report. Jpn J Clin Oncol 46 (2016), 875–878.
77. Kopecky, J, Trojanova, P, Kubecek, O, Kopecky, O, Treatment possibilities of ipilimumab-induced thrombocytopenia—case study and literature review. Jpn J Clin Oncol 45 (2015), 381–384.
78. Kanameishi, S, Otsuka, A, Nonomura, Y, Fujisawa, A, Endo, Y, Kabashima, K, Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann Oncol 27 (2016), 546–547.
79. Pushkarevskaya, A, Neuberger, U, Dimitrakopoulou-Strauss, A, Enk, A, Hassel, JC, Severe ocular myositis after ipilimumab treatment for melanoma: a report of 2 cases. J Immunother 40 (2017), 282–285.
80. Akhtari, M, Waller, EK, Jaye, DL, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 32 (2009), 322–324.
81. Richard, K, Weslow, J, Porcella, SL, Nanjappa, S, A case report of steroid responsive nivolumab-induced encephalitis. Cancer Control, 24, 2017 1073274817729069.
82. Stone, JH, Merkel, PA, Spiera, R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363 (2010), 221–232.
83. Xiao, B, Wang, Y, Li, W, et al. Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. Blood 122 (2013), 3365–3375.
84. Atarod, S, Ahmed, MM, Lendrem, C, et al. miR-146a and miR-155 expression levels in acute graft-versus-host disease incidence. Front Immunol, 7, 2016, 56.